Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin Journal Article
| Authors: | Xiao, H.; Mazumdar, M.; Bajorin, D. F.; Sarosdy, M.; Vlamis, V.; Spicer, J.; Ferrara, J.; Bosl, G. J.; Motzer, R. J. |
| Article Title: | Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin |
| Abstract: | Purpose: To assess the durability of response and overall survival far patients with good-risk metastatic germ cell tumors (GCT) treated with four cycles of etoposide and cisplatin (EP). Patients and Methods: Two hundred fourteen patients treated with EP an two consecutive randomized trials for good-risk metastatic GCT were the subject of this retrospective study. The response to therapy, relapse and survival status, and results of salvage therapy are reported. Results: One hundred ninety-five patients (91%) achieved a complete response (CR). This included 182 patients (85%) who achieved a CR to chemotherapy alone and 13 patients (6%) who achieved a CR to chemotherapy plus surgical resection of viable GCT. Seventeen patients (9%) have relapsed from CR. The median time to relapse was 10 months, and the longest duration from treatment to relapse was 36 months in a patient who received three of four planned courses of therapy. Eight patients who either achieved an incomplete response (IR) or relapsed were rendered continuously disease-free by salvage therapy and are alive. One hundred eighty-three patients (86%) are alive at a median fallow-up of 7.6 years. Conclusion: Four cycles of EP constitute effective therapy and can be offered to patients with good-risk GCT. In patients with intermediate and poor-risk GCT, clinical trials remain a priority to identify more effective treatment. |
| Keywords: | adolescent; adult; cancer survival; treatment outcome; disease-free survival; middle aged; survival analysis; retrospective studies; major clinical study; cancer recurrence; salvage therapy; cisplatin; cancer combination chemotherapy; antineoplastic agents; follow-up studies; etoposide; antineoplastic combined chemotherapy protocols; antineoplastic agents, phytogenic; risk; testis tumor; germ cell tumor; seminoma; germinoma; humans; prognosis; human; male; priority journal; article |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 15 |
| Issue: | 7 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 1997-07-01 |
| Start Page: | 2553 |
| End Page: | 2558 |
| Language: | English |
| PUBMED: | 9215824 |
| PROVIDER: | scopus |
| DOI: | 10.1200/JCO.1997.15.7.2553 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 17 March 2017 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work